Asset profile
Ventolin
Small molecule
Evidence outlook · registrational
Asthma: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2024-03) has passed without a status update. Check News for topline announcements.
MITCHELL (NCT06644924): The study randomized 118 participants to treatment sequences and used quadruple masking for PT007 and placebo, while Ventolin was open label; the primary outcome was the surrogate lung-function measure FEV1 AUC. Because the registry has no posted results, whether the primary endpoint was met is unknown, supporting a moderate evidence grade rather than a strong one.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
85 competitors in this universe: 23 direct rivals (same mechanism and indication), 2 same-class, 60 same-indication; 43 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Ventolin: this drug | Phase 3 | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Fluticasone Furoate / Vilanterol | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved | Combination | Glucocorticoid receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Olodaterol | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Proventil | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Salmeterol (DISKUS) | Approved | — | Beta-2 adrenergic receptor | ||
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | ||
| Albuterol (Ventolin) | Phase 3 | Small molecule | Beta-2 adrenergic receptor |
…and 70 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
17 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.